In May 2017 the newly named World Advanced Therapies & Regenerative Medicine Congress, will bring together 800+ attendees and explore the rapidly developing world of ATMPs (Advanced Therapy Medicinal Products). From clinical translation to commercialisation this congress will bring you the most exciting case studies and new data for stem cells, gene therapy, TCRs and gene editing. Experts in every area will help you tackle the process and regulatory hurdles of developing all new therapeutic formats all the way through manufacture and into the clinic. Taking place alongside the co-located 2nd annual World Precision Medicine Congress and 3rd annual Cord Blood World Europe, and hosting 200+ speakers, 7 tracks of content across the 3 days enabling networking opportunities with 800+ leading industry professionals. Choose the sessions which are most applicable to help your business plan for the future of ATMPs development and commercialisation.
Promethera's CEO Dr John Tchelingerian invited to present at the Biopharma commercialisation discussion session: Strategies for emerging bioscience and technology companies in Europe on Thursday 18th May at 12:00h GMT.
For more information on the Congress, click here.